Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 37 opinions in the last 12 months.
Pfizer Inc (PFE) is currently perceived as a value play in the pharmaceutical sector, with a secure dividend yield of around 6%. Experts note that while the company has a strong cash flow and a robust R&D pipeline, it has struggled to grow and deliver significant shareholder value since the COVID-19 pandemic. Acquisitions, particularly in oncology, have been under scrutiny, as some analysts believe they haven’t yet justified their costs. Overall, analysts express some caution, suggesting that there are better growth opportunities in the pharmaceutical space, yet many agree that the current stock price may present a buying opportunity for income-focused investors. With a consensus on its stable dividend, the sentiment leans towards long-term holding rather than immediate gains.
Once upon a time, he really liked it. Beaten up for inability to bring forward a weight-loss drug; that may or may not be a realistic critique of this stock long term. Analyst community is really...just...waiting. He sold last year, not ready to come back in. Solid company, an improved oncology pipeline might be a reason to get back in.
You'd have thought they'd be hit more by tariffs, as Trump hammers on that many drug components are made overseas. So the market must be thinking tariffs will benefit pharma, to explain why this name is up on such a tremendously down day. Keeping people guessing and on a knife's edge isn't a bug of the current US administration, it's a feature.
His healthcare investments focus on health management like UNH and medical devices.
If he's right about a correction in 2025, money managers will rotate into defensive areas like staples, utilities, healthcare and REITs. Their chart was in a big downtrend in recent years. PFE's chart has a double bottom this year. Relative strength is moving up. Also, volumes has popped around $25 (trough). The risk/reward is good. You're paid 6.5% to wait, too. $25 is big technical support.
(Analysts’ price target is $32.04)Pfizer Inc is a American stock, trading under the symbol PFE-N on the New York Stock Exchange (PFE). It is usually referred to as NYSE:PFE or PFE-N
In the last year, 23 stock analysts published opinions about PFE-N. 9 analysts recommended to BUY the stock. 9 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Pfizer Inc.
Pfizer Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Pfizer Inc.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
23 stock analysts on Stockchase covered Pfizer Inc In the last year. It is a trending stock that is worth watching.
On 2025-06-03, Pfizer Inc (PFE-N) stock closed at a price of $23.35.
Pays a 7% dividend. Something good must be coming out of their Seagen acquisition. The pipeline looks promising.